GLSV co-finances Sandoz spin-off Nabriva GmbH
Global Life Science Ventures (GLSV) announced the launch of Nabriva GmbH, a specialist antibiotic research and development company that has existed until now within Sandoz GmbH as the Vienna-based Antibiotic Research Institute (ABRI). GLSV is investing EUR6 million in a Series A financing round totalling EUR42 million, as part of a syndicate led by Nomura and also including Wellcome, HBM and Novartis Bioventures.
ABRI was originally founded in 2001 with the objective of discovering and developing new antibiotic compounds. With Sandoz's recent strategic re-orientation as the generics company within Novartis, it was decided to spin off ABRI and allow the late-preclinical stage company to develop outside of the Sandoz structure.
Nabriva will focus on the development of small molecule antibiotics for use in community and hospital infections. Nabriva has a strong pipeline of antibacterial drugs including three late preclinical projects and one product about to enter Phase 1 clinical trials. All the projects are based on families of small molecules with known antibiotic activity.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.